Navigation Links
Chronic pain: Watch out before accepting diagnosis and treatment
Date:9/8/2011

Bethesda, MDA new commentary published online in The FASEB Journal (http://www.fasebj.org) argues that patients should be diligent and demand proof of safety and benefit before beginning any treatment regimen for chronic pain, as some treatments have very little scientific evidence that they actually alleviate the conditions for which they are prescribed. In the article, Phillip J. Baker, Ph.D., Executive Director of the American Lyme Disease Foundation, dispels myths surrounding chronic Lyme disease, using it as an example of why patients should ensure that diagnostic and treatment tools are approved by the Food and Drug Administration and not just recommended by other patients and physicians.

"Despite repeated warnings by the Centers for Disease Control and Prevention and the Food and Drug Administration, the diagnosis of chronic Lyme disease often is based on the false results of non-standard test procedures, not approved by the FDA," said Baker. "This is inexcusable since 46 FDA-approved tests are available and used routinely by various state public health laboratories. A false diagnosis can result in patients being placed on prolonged antibiotic therapy or some other unproven and potentially harmful remedy."

Baker also says that before agreeing to undergo any treatment regimen for chronic pain, patients should ask their physician to provide results from published, placebo-controlled studies proving that the proposed remedy is both beneficial and safe. Testimonials by previously treated patientsregardless of the numberare not sufficient proof of benefit and safety. Unapproved and undocumented treatments are usually not covered by health insurance and therefore result in a huge financial burden to the patient. Chronic Lyme disease must be considered as part of a broad-based, multidisciplinary effort to understand the cause and treatment of chronic pain in general as outlined by the Institute of Medicine's report, "Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research" (http://www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx).

"When doctors don't know what's causing a patient to experience chronic pain, desperation can set in," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "That desperation, however, is no excuse for pushing the boundaries of the Hippocratic Oath by diagnosing a patient with a poorly defined health condition, like chronic Lyme disease, for which the only remedies are unproven and may only cause more harm."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Vitamin E shows possible promise in easing chronic inflammation
2. New research lights up chronic bacterial infection inside bone
3. When acute hepatitis develops into chronic hepatitis
4. Research uncovers promising target to treat chronic abdominal pain
5. New trigger for chronic inflammation in rheumatoid arthritis discovered
6. Early-life experience linked to chronic diseases later in life: UBC research
7. NHLBI awards $11 million for molecular roadmap to chronic lung diseases
8. New potential to treat chronic obstructive pulmonary disease
9. Higher opioid dose linked to overdose risk in chronic pain patients
10. Discovery of new type of immune cells regulating inflammation in chronic diseases
11. New data on highly effective treatment for chronic rhinosinusitis with nasal polyps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):
(Date:6/20/2017)... ... 20, 2017 , ... CTNext , Connecticut’s go-to resource ... a Higher Education Entrepreneurship Advisory Committee to implement the recommendations of the master ... representatives from 35 higher education institutions across the state over the past six ...
(Date:6/20/2017)... Pa. , June 20, 2017  Kibow Biotech ... pleased to announce the issuance of a new patent ... or hyperuricemia by the U.S. Patent and Trademark Office ... a winner of the Buzz of Bio award in ... is akin to developing non-drug approaches to chronic disease. ...
(Date:6/20/2017)... ... June 20, 2017 , ... GigaGen Inc ... millions-diverse immune repertoires, announces launch of its new Surge(TM) Discovery service ... CEO of GigaGen, will present on Surge at the conference. , Surge is ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has been ... One of the biggest challenges faced by life sciences, biotech and pharmaceuticals companies today ... is Kati Abraham , who is well known in the industry and brings ...
Breaking Biology Technology: